Get started
Live feed
PRReleasevia Quantisnow
Solid Biosciences Inc. logo

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for SLDB

Across the 15 sessions after earlier SLDB headlines, the stock closed higher 6 times and lower 9 times, with a median move of 4.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

SLDB close-to-close change in the session after earlier headlines
SessionEarlier headlineSLDBSPY
Jan 14, 2026Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101+12.6%-0.5%
Jan 13, 2026Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia-1.5%-0.2%
Jan 12, 2026Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia-0.9%+0.2%
Jan 6, 2026Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conferenceand 1 other headline that session+3.0%+0.6%
Dec 17, 2025Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services-7.6%-1.1%
Dec 8, 2025Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum-1.0%-0.3%

Keep researching SLDB

Quantisnow market dataNASDAQ
Solid Biosciences Inc. logo
SLDB
Solid Biosciences Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2018
Get push alerts for SLDB

Follow SLDB and get a push notification the moment its next story breaks.

Full SLDB profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLDB (Solid Biosciences Inc.) and more on Quantisnow.